Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Subscribe To Our Newsletter & Stay Updated